Luiz Pedro Sório de Carvalho, Ph.D., MRC National Institute for Medical Research, London, United Kingdom, is one of two recipients of the 2014 Merck Irving S. Sigal Memorial Awards. These awards are presented in honor of Irving Sigal, who was instrumental in the early discovery of therapies to treat HIV/AIDS.
De Carvalho received his Ph.D. in Biochemistry from the Albert Einstein College of Medicine and went on to complete his training as a postdoctoral fellow at Weill Cornell Medical College in 2011. De Carvalho has already made major contributions to our understanding of the metabolism of Mycobacterium tuberculosis that have facilitated new approaches to chemotherapy. He established a novel activity-based metabolic profiling approach to identify the roles of enzymes of previously unknown functions and revealed aspects of carbon metabolism in M. tuberculosis that are very different to those found in other bacteria. He also worked on the discovery and characterization of lead compounds that target non-replicating M. tuberculosis, including nitazoxanide. Nominator Sabine Ehrt, Weill Cornell Medical College, says, “de Carvalho has truly moved the tuberculosis research field forward.”
As a young investigator, de Carvalho has authored 25 peer-reviewed articles. He is a reviewer for several journals including Science, PNAS, and Nature Chemical Biology, as well as funding agencies, such as the Wellcome Trust, Medical Research Council, and the Biotechnology and Biological Sciences Research Council. Recently, de Carvalho was awarded an MRC Centenary Early Career Award for his accomplishments.
Back to the Merck Irving S. Sigal Memorial Awards